HARVARD BIOSCIENCE Business Summary

Harvard Bioscience Inc. (HBIO) operates as a global developer and manufacturer of specialized technologies for life science research, pharmaceutical discovery, and preclinical testing. The company generates revenue through a mix of high-precision scientific instruments, software, and a growing portfolio of high-margin consumables, which currently account for approximately 55% of total recurring revenue. Its operations are organized around two primary pillars: Preclinical research tools, including the gold-standard DSI telemetry and Buxco respiratory systems, and the emerging Translational Science segment, which focuses on bridging in vivo and in vitro research through organoid and 3D biology platforms like MeshMEA and Incub8. Positioned as a specialized micro-cap player in the life sciences tools sector, HBIO competes directly with industry giants such as Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation, distinguishing itself by providing niche, high-fidelity data solutions for complex physiological monitoring that larger generalists often overlook. Leadership is currently spearheaded by President and CEO John Duke, who assumed the role in July 2025 following a successful tenure as CEO of Plastic Molding Technology and over 20 years of executive experience at Corning Incorporated, specifically within its Life Sciences division. He is supported by Interim CFO and Treasurer Mark Frost, a veteran financial executive with prior CFO roles at Fathom and Argon Medical Devices, and Nitya Shetty, Vice President of Global Research and Development, who brings over two decades of engineering leadership from Spacelabs Healthcare and GE. The company’s strategic direction is further influenced by a board featuring notable industry figures such as Stephen DeNelsky, a Managing Director at Oaktree Capital Management, and William A. Snider of BroadOak Capital Partners. Institutional backing remains significant for its valuation tier, with major positions held by Goldman Sachs, Vanguard Group, and BlackRock, reflecting continued investor interest in the company’s 2026 strategic pivot toward higher-margin recurring revenue streams.